Organization
Legorreta Cancer Center
17 abstracts
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
Demographics of cancer screening in Providence’s homeless population.Org: Rhode Island Hospital, Legorreta Cancer Center, Brown University School of Medicine-Rhode Island Hospital, Providence, RI, Brown Physicians Inc,
Abstract
Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT.Org: Legorreta Cancer Center at Brown University, Brown University School of Medicine-Rhode Island Hospital, University of Minnesota, Sarah Cannon Research Institute/Tennessee Oncology, Brown Unversity School of Medicine-Rhode Island Hospital,
Abstract
Synergistic inhibition of CXCL8 following MRTX1133 treatment with ONC212 or 5-FU in KRAS G12D and G12V mutant CRC and PDAC cell lines.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Providence, RI,
Abstract
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Mayo Clinic, Actuate Therapeutics, Inc., Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Legorreta Cancer Center at Brown University,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.Org: Next Oncology Virginia and Virginia Cancer Specialists, Sir Charles Gairdner Hospital, Calvary Mater Hospital, University of Vermont Cancer Center, Stephenson Cancer Center,
Abstract
ITGB6 as an inhibitor of T-cell killing via modulation of paracrine TGFβ signaling in pancreatic ductal adenocarcinoma.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Providence, RI,
Abstract
The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update.Org: The UT MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Unity Point Health, OU Health Stephenson Cancer Center, Women’s Hospital,
Abstract
Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.Org: Caris Life Sciences, Irving, TX, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, University of Southern California/Norris Comprehensive Cancer Center,
Abstract
Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.Org: Legorreta Cancer Center, Brown University - Lifespan Cancer Institute, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Clinical Research Institute at Rambam, Rambam Medical Center,
Abstract
In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.Org: Lantern Pharma, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, Brown University Warren Alpert Medical School, Winship Cancer Institute of Emory University, DTC,
Abstract
Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors.Org: Legorreta Cancer Center, Brown University - Lifespan Cancer Institute, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Highlands Oncology,
Abstract
GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.Org: Legorreta Cancer Center at Brown University, Providence, RI, Brown University - Lifespan Cancer Institute, NanoString Technologies, Inc., Seattle, WA,
Abstract
Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.Org: Legorreta Cancer Center, Winship Cancer Institute of Emory University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, DTC, Actuate Therapeutics, Inc.,
Abstract
Androgen receptor inhibitors and anti-NKG2A checkpoint inhibitor to enhance NK cell–mediated killing of prostate cancer cell lines in vitro.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Rhode Island Hospital, Cancer Center at Brown University,
Abstract
Combination of 5-FU plus KRAS G12D inhibitor MRTX1133 against human colorectal and pancreatic cancer cells and the affects on inhibition of pERK and immune-stimulatory cytokine patterns in in KRAS G12D and KRAS G12V tumor cells.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Providence, RI, Legorreta Cancer Center at Brown University, Brown University, Providence, RI,
Abstract
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, University of Pittsburgh Medical Center (UPMC), Department of Medicine, Icahn School of Medicine at Mount Sinai,